{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:27:02Z","timestamp":1783117622176,"version":"3.54.6"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"inventageLab"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s12325-024-02890-1","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T08:03:06Z","timestamp":1717488186000},"page":"2936-2952","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Phase I, Open-Label, Sequential, Single-Dose Clinical Trial to Evaluate the Pharmacokinetic, Pharmacodynamic, and Safety of IVL3001, a Finasteride-Based Novel Long-Acting Injection for Androgenetic Alopecia"],"prefix":"10.1007","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct04945226","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Heesun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choongho","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mase","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeong-Ryoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4778-3041","authenticated-orcid":false,"given":"Juhee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"issue":"10","key":"2890_CR1","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.4065\/80.10.1316","volume":"80","author":"D Stough","year":"2005","unstructured":"Stough D, Stenn K, Haber R, Parsley WM, Vogel JE, Whiting DA, et al. Psychological effect, pathophysiology, and management of androgenetic alopecia in men. Mayo Clin Proc. 2005;80(10):1316\u201322.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2890_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1365-2133.1977.tb15179.x","volume":"97","author":"E Ludwig","year":"1977","unstructured":"Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977;97(3):247\u201354.","journal-title":"Br J Dermatol."},{"key":"2890_CR3","doi-asserted-by":"crossref","unstructured":"Cash TF. The psychology of hair loss and its implications for patient care. Clin Dermatol. 2001 Mar-Apr;19(2):161\u20136.","DOI":"10.1016\/S0738-081X(00)00127-9"},{"issue":"7162","key":"2890_CR4","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/bmj.317.7162.865","volume":"317","author":"R Sinclair","year":"1998","unstructured":"Sinclair R. Male pattern androgenetic alopecia. BMJ. 1998;317(7162):865\u20139.","journal-title":"BMJ"},{"key":"2890_CR5","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1185\/030079905X61820","volume":"21","author":"M Alfonso","year":"2005","unstructured":"Alfonso M, Richter-Appelt H, Tosti A, Viera MS, Garc\u00eda M. The psychosocial impact of hair loss among men: a multinational European study. Curr Med Res Opin. 2005;21(11):1829\u201336.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"2890_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.5021\/ad.2012.24.3.311","volume":"24","author":"SH Han","year":"2012","unstructured":"Han SH, Byun JW, Lee WS, Kang H, Kye YC, Kim KH, et al. Quality of life assessment in male patients with androgenetic alopecia: result of a prospective, multicenter study. Ann Dermatol. 2012;24(3):311\u20138.","journal-title":"Ann Dermatol"},{"issue":"1","key":"2890_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1677\/joe.0.0570111","volume":"57","author":"KD Bingham","year":"1973","unstructured":"Bingham KD, Shaw DA. The metabolism of testosterone by human male scalp skin. J Endocrinol. 1973;57(1):111\u201321.","journal-title":"J Endocrinol"},{"issue":"1","key":"2890_CR8","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/s41598-022-05544-w","volume":"12","author":"S-I Yun","year":"2022","unstructured":"Yun S-I, Lee S-K, Goh E-A, Kwon OS, Choi W, Kim J, et al. Weekly treatment with SAMiRNA targeting the androgen receptor ameliorates androgenetic alopecia. Sci Rep. 2022;12(1):1607.","journal-title":"Sci Rep."},{"issue":"3","key":"2890_CR9","doi-asserted-by":"publisher","first-page":"e13379","DOI":"10.1111\/dth.13379","volume":"33","author":"R Dhurat","year":"2020","unstructured":"Dhurat R, Sharma A, Rudnicka L, Kroumpouzos G, Kassir M, Galadari H, et al. 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety. Dermatol Ther. 2020;33(3):e13379.","journal-title":"Dermatol Ther."},{"issue":"12","key":"2890_CR10","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1111\/j.1743-6109.2008.01001.x","volume":"5","author":"F Erdemir","year":"2008","unstructured":"Erdemir F, Harbin A, Hellstrom WJ. 5-alpha reductase inhibitors and erectile dysfunction: the connection. J Sex Med. 2008;5(12):2917\u201324.","journal-title":"J Sex Med."},{"key":"2890_CR11","doi-asserted-by":"crossref","unstructured":"Mysore V, Shashikumar BM. Guidelines on the use of finasteride in androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2016 Mar-Apr;82(2):128\u201334.","DOI":"10.4103\/0378-6323.177432"},{"issue":"1","key":"2890_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1046\/j.1523-1747.2003.12167.x","volume":"8","author":"J Shapiro","year":"2003","unstructured":"Shapiro J, Kaufman KD. Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss). J Investig Dermatol Symp Proc. 2003;8(1):20\u20133.","journal-title":"J Investig Dermatol Symp Proc."},{"key":"2890_CR13","volume-title":"Syed K","author":"PMBK Zito","year":"2022","unstructured":"Zito PM, Bristas KG, Syed K. Finasteride. StatPearls Publishing; 2022."},{"issue":"6","key":"2890_CR14","first-page":"2409","volume":"43","author":"JH Kim","year":"2019","unstructured":"Kim JH, Na J, Bak DH, Lee BC, Lee E, Choi MJ, et al. Development of finasteride polymer microspheres for systemic application in androgenic alopecia. Int J Mol Med. 2019;43(6):2409\u201319.","journal-title":"Int J Mol Med"},{"issue":"2","key":"2890_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000492035","volume":"5","author":"AM Hosking","year":"2019","unstructured":"Hosking AM, Juhasz M, Atanaskova MN. Complementary and Alternative Treatments for Alopecia: A Comprehensive Review. Skin Appendage Disord. 2019;5(2):72\u201389.","journal-title":"Skin Appendage Disord"},{"issue":"5","key":"2890_CR16","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/2045125314540297","volume":"4","author":"S Brissos","year":"2014","unstructured":"Brissos S, Veguilla MR, Taylor D, Balanza-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4(5):198\u2013219.","journal-title":"Ther Adv Psychopharmacol"},{"key":"2890_CR17","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.2147\/NDT.S309768","volume":"17","author":"M Zolezzi","year":"2021","unstructured":"Zolezzi M, Abouelhassan R, Eltorki Y, Haddad PM, Noorizadeh M. Long-Acting Injectable Antipsychotics: A Systematic Review of Their Non-Systemic Adverse Effect Profile. Neuropsychiatr Dis Treat. 2021;17:1917\u201326.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2890_CR18","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fphar.2014.00174","volume":"5","author":"T Tuntland","year":"2014","unstructured":"Tuntland T, Ethell B, Kosaka T, Blasco F, Zang RX, Jain M, et al. Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research. Front Pharmacol. 2014;5:174.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2890_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00003495-199957010-00014","volume":"57","author":"KJ McClellan","year":"1999","unstructured":"McClellan KJ, Markham A. Finasteride: a review of its use in male pattern hair loss. Drugs. 1999;57(1):111\u201326.","journal-title":"Drugs."},{"issue":"12","key":"2890_CR20","first-page":"2563","volume":"30","author":"DE Furst","year":"2003","unstructured":"Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003;30(12):2563\u201371.","journal-title":"J Rheumatol."},{"issue":"1","key":"2890_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35\u201345.","journal-title":"Arthritis Rheum"},{"key":"2890_CR22","doi-asserted-by":"crossref","unstructured":"Bossie CA, Alphs LD, Correll CU. Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs. International Clinical Psychopharmacology. 2015;30(5).","DOI":"10.1097\/YIC.0000000000000082"},{"key":"2890_CR23","doi-asserted-by":"crossref","unstructured":"Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol. 2013 Aug;66(8 Suppl):S37\u201341.","DOI":"10.1016\/j.jclinepi.2013.01.012"},{"issue":"2","key":"2890_CR24","first-page":"17","volume":"49","author":"N Poloni","year":"2019","unstructured":"Poloni N, Ielmini M, Caselli I, Lucca G, Gasparini A, Gasparini A, et al. Oral Antipsychotic Versus Long-Acting Injections Antipsychotic in Schizophrenia Spectrum Disorder: a Mirror Analysis in a Real-World Clinical Setting. Psychopharmacol Bull. 2019;49(2):17\u201327.","journal-title":"Psychopharmacol Bull"},{"issue":"6","key":"2890_CR25","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1111\/j.1365-2125.2008.03124.x","volume":"65","author":"DA Hughes","year":"2008","unstructured":"Hughes DA. Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens. Br J Clin Phrmacol. 2008;65(6):871\u20138.","journal-title":"Br J Clin Phrmacol."},{"issue":"16","key":"2890_CR26","first-page":"18","volume":"64","author":"L Ereshefsky","year":"2003","unstructured":"Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry. 2003;64(16):18\u201323.","journal-title":"J Clin Psychiatry"},{"key":"2890_CR27","doi-asserted-by":"crossref","unstructured":"Macdougall IC, Padhi D, Jang G. Pharmacology of darbepoetin alfa. Nephrology Dialysis Transplantation. 2007;22(suppl_4):iv2-iv9.","DOI":"10.1093\/ndt\/gfm160"},{"issue":"6","key":"2890_CR28","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/cpdd.798","volume":"9","author":"Z Li","year":"2020","unstructured":"Li Z, Radin A, Li M, Hamilton JD, Kajiwara M, Davis JD, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of dupilumab in healthy adult subjects. Clin Pharmacol drug Dev. 2020;9(6):742\u201355.","journal-title":"Clin Pharmacol drug Dev."},{"issue":"2","key":"2890_CR29","first-page":"148","volume":"20","author":"JR Carlin","year":"1992","unstructured":"Carlin JR, H\u00f6glund P, Eriksson L, Christofalo P, Gregoire SL, Taylor AM, et al. Disposition and pharmacokinetics of [14C] finasteride after oral administration in humans. Drug Metab Dispos. 1992;20(2):148\u201355.","journal-title":"Drug Metab Dispos"},{"key":"2890_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/BF03189869","volume":"16","author":"M Ohtawa","year":"1991","unstructured":"Ohtawa M, Morikawa H, Shimazaki J. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5\u03b1-androst-1-ene-17\u03b2-carboxamide, a new type of specific competitive inhibitor of testosterone 5\u03b1-reductase, in volunteers. Eur J Drug Metab Pharmacokinet. 1991;16:15\u201321.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"2890_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10243","volume":"7","author":"T Le","year":"2022","unstructured":"Le T, Aguilar B, Mangal JL, Acharya AP. Oral drug delivery for immunoengineering. Bioeng Transl Med. 2022;7(1): e10243.","journal-title":"Bioeng Transl Med"},{"issue":"3","key":"2890_CR32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1046\/j.1365-2133.2001.04399.x","volume":"145","author":"DA Buckley","year":"2001","unstructured":"Buckley DA, Du Vivier AW. The therapeutic use of topical contact sensitizers in benign dermatoses. Br J Dermatol. 2001;145(3):385\u2013405.","journal-title":"Br J Dermatol"},{"issue":"1","key":"2890_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00003495-199957010-00014","volume":"57","author":"KJ McClellan","year":"1999","unstructured":"McClellan KJ, Markham A. Finasteride: a review of its use in male pattern hair loss. Drugs. 1999;57(1):111\u201326.","journal-title":"Drugs"},{"issue":"1","key":"2890_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2165\/00003088-199630010-00002","volume":"30","author":"JF Steiner","year":"1996","unstructured":"Steiner JF. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet. 1996;30(1):16\u201327.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"2890_CR35","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nrd3439","volume":"10","author":"J Arrowsmith","year":"2011","unstructured":"Arrowsmith J. Trial watch: Phase II failures: 2008\u20132010. Nat Rev Drug Discov. 2011;10(5):328\u20139.","journal-title":"Nat Rev Drug Discov."},{"issue":"1","key":"2890_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.12793\/tcp.2019.27.1.19","volume":"27","author":"HS Lim","year":"2019","unstructured":"Lim HS. Evolving role of modeling and simulation in drug development. Transl Clin Pharmacol. 2019;27(1):19\u201323.","journal-title":"Transl Clin Pharmacol"},{"issue":"2","key":"2890_CR37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00002018-200730020-00001","volume":"30","author":"RO Day","year":"2007","unstructured":"Day RO, Williams KM. Open-label extension studies. Drug Saf. 2007;30(2):93\u2013105.","journal-title":"Drug Saf"},{"issue":"1","key":"2890_CR38","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1186\/1745-6215-15-456","volume":"15","author":"BC Kahan","year":"2014","unstructured":"Kahan BC, Cro S, Dor\u00e9 CJ, Bratton DJ, Rehal S, Maskell NA, et al. Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials. Trials. 2014;15(1):456.","journal-title":"Trials"},{"issue":"4","key":"2890_CR39","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/annonc\/mdy035","volume":"29","author":"JC Trone","year":"2018","unstructured":"Trone JC, Ollier E, Chapelle C, Bertoletti L, Cucherat M, Mismetti P, et al. Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events\u2014a meta-analysis. Anna Oncol. 2018;29(4):803\u201311.","journal-title":"Anna Oncol"},{"key":"2890_CR40","doi-asserted-by":"publisher","first-page":"204512532199127","DOI":"10.1177\/2045125321991278","volume":"11","author":"C Paton","year":"2021","unstructured":"Paton C, Craig TKJ, McConnell B, Barnes TRE. Side-effect monitoring of continuing LAI antipsychotic medication in UK adult mental health services. Ther Adv Psychopharmacol. 2021;11:2045125321991278.","journal-title":"Ther Adv Psychopharmacol"},{"key":"2890_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199586042.001.0001","volume-title":"Antipsychotic long-acting injections","author":"P Haddad","year":"2010","unstructured":"Haddad P, Fleischhacker WW. 47 Adverse effects and antipsychotic long-acting injections. In: Haddad P, Lambert T, Lauriello J, editors. Antipsychotic long-acting injections. Oxford: Oxford University Press; 2010."},{"issue":"6","key":"2890_CR42","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1111\/j.1743-6109.2011.02255.x","volume":"8","author":"MS Irwig","year":"2011","unstructured":"Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8(6):1747\u201353.","journal-title":"J Sex Med"},{"issue":"1","key":"2890_CR43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/2229-5178.93496","volume":"3","author":"V Mysore","year":"2012","unstructured":"Mysore V. Finasteride and sexual side effects. Indian Dermatol Online J. 2012;3(1):62\u20135.","journal-title":"Indian Dermatol Online J"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02890-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02890-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02890-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T22:01:25Z","timestamp":1719612085000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02890-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2890"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02890-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"assertion":[{"value":"25 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the clinical trial is related to drugs with commercial significance, and no conflicts of interest may influence the objectivity and integrity of the study process.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted according to the Therapeutic Goods Administration (TGA) and Human Research Ethics Committee (HREC) guidelines. The whole study was conducted in accordance with the provisions of the Helsinki Declaration and the standards for clinical trial management (GCP), and the protocol was registered at  (NCT04945226; Reg date 2021\u201306-30).\u00a0Potential volunteers completed signed informed consent and underwent a screening test prior to the trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}